Soon Choi, MD
Internal Medicine · Fenton, MINPI 1821088162
Payments from drug & device makers
Across 435 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amarin Pharma, Inc.$1K
- Amgen$1K
- GSK$789
- AstraZeneca$622
- Pfizer$513
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,827100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,380 |
| Amarin Pharma, Inc. | 39 | $1,146 |
| Amgen | 44 | $1,036 |
| GSK | 38 | $789 |
| AstraZeneca | 30 | $622 |
| Pfizer | 25 | $513 |
| Lilly USA, LLC | 26 | $492 |
| Johnson & Johnson | 13 | $352 |
| Gilead | 15 | $336 |
| Boehringer Ingelheim | 14 | $315 |
| Ardelyx, Inc. | 9 | $300 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $299 |
| Nestle Healthcare Nutrition Inc. | 12 | $255 |
| Merck | 13 | $252 |
| Ironwood Pharmaceuticals, Inc | 11 | $237 |
| Novo Nordisk | 11 | $231 |
| Sumitomo Pharma America, Inc. | 6 | $152 |
| Novartis | 4 | $118 |
| Aimmune Therapeutics, Inc. | 5 | $113 |
| Radius Health, Inc. | 5 | $112 |
| Astellas Pharma US Inc | 6 | $111 |
| Scilex Pharmaceuticals Inc. | 6 | $108 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
| Vivus LLC | 4 | $80 |
| Genentech USA, Inc. | 4 | $72 |
| Bayer | 3 | $60 |
| Eisai Inc. | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Abbott | 2 | $45 |
| Boston Scientific | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $30 |
| Redhill Biopharma Inc. | 1 | $25 |
| Celltrion, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$249
How this compares
$9,852 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 121 | $148,670 |
| JardianceEmpagliflozin | 92 | $80,661 |
| JanuviaSitagliptin Phosphate | 73 | $61,754 |
| VascepaIcosapent Ethyl | 141 | $53,198 |
| FarxigaDapagliflozin Propanediol | 61 | $43,000 |
| ProliaDenosumab | 22 | $37,445 |
| TrulicityDulaglutide | 25 | $25,988 |
| OzempicSemaglutide | 19 | $25,086 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $24,085 |
| RybelsusSemaglutide | 15 | $20,935 |
| TradjentaLinagliptin | 27 | $19,215 |
| LinzessLinaclotide | 27 | $17,720 |
| GemtesaVibegron | 27 | $17,533 |
| ZenpepLipase/Protease/Amylase | 22 | $15,786 |
| EliquisApixaban | 21 | $15,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $1,380 | $174,626161 claims |
| Boehringer IngelheimJardiance, Tradjenta | $315 | $99,876119 claims |
| MerckJanuvia, Janumet | $252 | $85,83996 claims |
| Novo NordiskOzempic, Rybelsus | $231 | $46,02034 claims |
| AstraZenecaFarxiga | $622 | $43,00061 claims |
| AmgenProlia | $1,036 | $37,44522 claims |
| Lilly USA, LLCTrulicity | $492 | $25,98825 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $152 | $17,53327 claims |
| Aimmune Therapeutics, Inc.Zenpep | $113 | $15,78622 claims |
| PfizerEliquis | $513 | $15,40221 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $108 | $15,23323 claims |
| Johnson & JohnsonXarelto | $352 | $11,15020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Fenton
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.